Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-026 for Gout
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • 225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • LIFE Offering
    • SEDAR+
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News
Mar 01, 2021 7:00am EST

XORTX Participating in WuXI Healthcare Forum

Feb 17, 2021 11:35am EST

XORTX to Present at BIO CEO and Investor Conference; Strategies to Decrease Acute and Chronic Kidney Injury, Co-morbidity and Mortality

Feb 17, 2021 7:00am EST

XORTX to Present at BIO CEO and Investor Conference

Feb 10, 2021 7:00am EST

XORTX Closes Over Subscribed Private Placement

Feb 08, 2021 7:40am EST

XORTX Announces Over Subscribed Private Placement

Jan 19, 2021 10:10am EST

XORTX Provides Corporate Update; Synopsis of 2020 Achievements and Key Activities for 2021

Jan 19, 2021 6:55am EST

XORTX Provides Corporate Update

Jan 12, 2021 7:00am EST

XORTX Grants Options

Dec 29, 2020 7:00am EST

XORTX Announces Grant of European Patent

Nov 16, 2020 8:54am EST

XORTX Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study

  • arrow_back
  • 1…
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • arrow_forward
rss_feed News RSS
©2025 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap